Insider Transactions in Q3 2024 at Athira Pharma, Inc. (ATHA)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 05
2024
|
Rachel Lenington COO and CDO |
SELL
Open market or private sale
|
Direct |
2,525
-10.79%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Andrew Gengos CFO and Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,272
-1.29%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Mark James Litton President and CEO |
SELL
Open market or private sale
|
Direct |
5,032
-3.06%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Mark Worthington General Counsel and CCO |
SELL
Open market or private sale
|
Direct |
2,525
-4.64%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,525
-2.65%
|
$0
$0.57 P/Share
|
|
Sep 03
2024
|
Rachel Lenington COO and CDO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+29.94%
|
-
|
|
Sep 03
2024
|
Andrew Gengos CFO and Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+4.82%
|
-
|
|
Sep 03
2024
|
Mark James Litton President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+10.85%
|
-
|
|
Sep 03
2024
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+15.52%
|
-
|
|
Sep 03
2024
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+9.5%
|
-
|